E-7820
Chronic Myelomonocytic Leukemia
Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
97 Active assets in the Chronic Myelomonocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pevonedistat Takeda | Phase 3 | BB |
Venetoclax Servier Bio-Innovation LLC | Phase 2/3 | BB |
Azacitidine The University of Hong Kong | Phase 3 | BB |
Evomela City of Hope Medical Center | Phase 2 | BB |
Astx727 Taiho Oncology, Inc. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
E-7820 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →